Roche’s ADR grew over 10% from $40 levels in the beginning of this year to $45 levels as of April 22, compared to a 13% decline for the broader S&P 500. While Roche’s ADR has outperformed the broader markets, we believe there is still 10% upside potential from the current levels…
Source: Forbes Markets
